Clinical data investigation identifies MARK3 as an oncogenic driver in castration-resistant prostate cancer.

ABSTRACT: Castration-resistant prostate cancer (CRPC) represents an aggressive and fatal form of prostate cancer that emerges following resistance to androgen deprivation therapy. Despite the availability of various drugs that can enhance the quality and prolong the survival of CRPC patients, resistance to these therapies is frequently observed, making the disease increasingly difficult to treat. Altered expression of kinases and phosphatases is a critical driver of CRPC and presents a potential target for more effective treatments. In this study, we have performed comprehensive transcriptomic analysis of ∼359 normal and CRPC patient samples from The Cancer Genome Atlas to identify the differentially expressed kinases and phosphatases in patient samples. We shortlisted the candidate genes based on t

SUBMITTER: Raut R 

PROVIDER: S-EPMC12004708 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature